New drug combo for relapsed NKT-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination of three drugs (selinexor, an anti-PD-1 antibody, and a chemotherapy regimen called P-GemOx) for people with NKT-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a specific type of lymphoma called NKT-cell lymphoma (nasal type) and it has come back or not responded to previous treatment.
- You have already received a standard treatment that included the drug asparaginase.
- You are between 14 and 75 years old and your doctor thinks you are likely to live more than 3 months.
- Your overall health is fairly good (able to care for yourself and be up and about some of the day) and your blood counts and organ function meet certain minimum levels.
- You do not have active autoimmune disease or other serious medical conditions that would interfere with the study, and you agree to avoid pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.